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ABSTRACT
Background Prescription sequence symmetry analysis (PSSA) is a signal detection method for adverse drug events. Its capacity to con-
sistently detect adverse drug events across different settings has not been tested. We aimed to determine the consistency of PSSA results
for detecting positive and negative control adverse drug events across different settings.
Methods Using a distributed network model, we analyzed prescription dispensing data using PSSA in Australia, Hong Kong, Japan,
Korea, and Taiwan. Positive control was amiodarone and thyroxine, as a marker of amiodarone-induced hypothyroidism, a known adverse
event with a clear temporal relationship to amiodarone initiation. Negative controls were amiodarone and allopurinol, as a marker of
amiodarone-induced gout and thyroxine and allopurinol, as a marker of thyroxine-induced gout. Gout is not recorded as an adverse event
in product information for either medicine. Adjusted sequence ratios (ASR) were calculated for each country. Pooled estimates were obtained
by using the generic inverse variance method.
Results A positive association was identiﬁed between amiodarone and thyroxine in all settings with a pooled ASR 2.63 (95% conﬁdence
interval (CI) 1.47–4.72). Temporal analysis showed the effect occurred within the ﬁrst few weeks of treatment. No signiﬁcant associations
were found for the negative controls in any setting; pooled ASR were 0.76 (95%CI 0.62–0.93) and 0.98 (95%CI 0.85–1.12) for amiodarone-
allopurinol and thyroxine-allopurinol, respectively.
Conclusion Despite different health settings, different populations, and different patterns of medicine utilization, PSSA gave consis-
tent estimates across countries for a well-known positive association and two negative control adverse events. © 2015 The Authors
Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
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BACKGROUND
Prescription sequence symmetry analysis (PSSA) is a
signal detection method for adverse drug events utiliz-
ing administrative claims data.1 The method has the
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potential to become a tool to assist in global
pharmacosurveillance of medicines, complementary
to other methods, because of its ease of application.
The method employs a simple algorithm, is computa-
tionally fast, and requires a minimal dataset of only
three variables: drug name, date of supply, and a pa-
tient identiﬁer. This minimal dataset is usually cap-
tured in electronically held prescription dispensing
datasets, which are available in many developed coun-
tries, thus enabling multi-country analyses.
We have previously shown that PSSA has a sensi-
tivity of 61%, a speciﬁcity of 93%, a positive predic-
tive value of 77%, and a negative predictive value of
87% using adverse events identiﬁed in randomized
controlled trials as the gold standard for positive
events and using negative controls of adverse events
identiﬁed in product information of unrelated prod-
ucts.2 We have also shown the feasibility of the
method in a distributed network model to undertake
multi-country analyses.3
The Bradford Hill criteria for causal association
identify temporality and consistency as important
criteria for assessing causation of events.4 One of
the advantages of PSSA over other methods is that
a visualization of temporal association is created in
addition to the statistical output of an adjusted se-
quence ratio. By applying the method across multi-
ple datasets, we also have the opportunity to test
consistency across time. Thus, PSSA is a potentially
valuable method for assessing both temporality and
consistency. In our prior study, where we assessed
the association between antipsychotics and acute
hyperglycaemia,3 we found that the adjusted analy-
ses for individual medicines were similar in the di-
rection of the associations across countries;
however, some countries had outlying results. Dif-
ferences between countries in terms of stigma asso-
ciated with mental health treatment were postulated
as one of the reasons for the discrepancy. For this
reason, the present validation study aimed to iden-
tify whether a well-known medicine adverse event
that was unlikely to be confounded by health sys-
tem factors could be consistently detected across
countries.
In this study, we aimed to assess whether PSSA pro-
vides temporally associated and consistent results
across multiple datasets in different countries.
This research was undertaken utilizing the network
of databases established as part of the Asian
Pharmacoepidemiology network (AsPEN).5 AsPEN
enables studies to be undertaken in datasets within dif-
ferent countries, with different ethnic groupings and
different health systems and regulations.
METHOD
In selecting the positive control, we identiﬁed a medi-
cine that was available in every country and had a
well-documented adverse event for which there was
a speciﬁc prescription treatment and for which there
was evidence of a temporal association. The positive
control, or known adverse event, in this study was
amiodarone-induced hypothyroidism. Amiodarone is
an antiarrhythmic agent that contains iodine in its
chemical structure and is known to exert effect on
the thyroid gland6 with an estimated incidence of thy-
roid dysfunction of 15–20% in persons taking amioda-
rone.7 Amiodarone-induced hypothyroidism has been
reported to occur early in the course of therapy and
has an incidence of approximately 5–7%;8–10 thus,
we would expect to see a temporal association of the
adverse event with initiation. A nested case–control
study found the risk of hypothyroidism was increased
more than sixfold (Odds ratio 6.6, 95% conﬁdence
interval (CI) 3.9–11.1) in those taking amiodarone.11
A meta-analysis of adverse events from randomized
controlled trials comparing amiodarone with placebo
that grouped adverse events by organ class found a
fourfold increased risk (OR 4.2, 95%CI 2.0–8.7) of
adverse thyroid events with amiodarone.12 For the
negative controls, or known negative events, we
assessed amiodarone-induced allopurinol prescribing
and thyroxine-induced allopurinol prescribing. Allo-
purinol, which is indicated for prevention of gout but
not acute treatment of gout, was chosen as the negative
control because neither amiodarone nor thyroxine is
known to be associated with gout.13 Furthermore, given
allopurinol is indicated for prevention, but not for
treatment of an acute gout event, it is unlikely to be
prescribed, even if a previously unrecognized adverse
event occurred.
The AsPEN participants in this study were based
in Australia, Hong Kong, Japan, Korea, and Taiwan.
The datasets have been described previously.5 The
Australian Government Department of Veterans’
Affairs healthcare claims database (Australia, 2001–
2012) contains dispensing records for all veterans
and their dependents in Australia (approximately
300000) and represents a predominantly elderly co-
hort. The Korea Health Insurance Review and As-
sessment Service database (Korea, 2006–2008)
includes all subsidized medicines for the entire pop-
ulation of approximately 50 million persons. The
National Health Insurance Research Database
(Taiwan, 2002–2008) includes all subsidized medi-
cines covering the entire population; a random
sample of one million persons was included in this
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study. The Hong Kong dataset was the Clinical Data
Analysis and Reporting System from the Hong Kong
Hospital Authority (2008–2012). The Hong Kong
dataset includes data from publicly funded hospitals
and primary care general physician services via the
outpatient clinics in hospitals and general outpatient
clinics in the community. The service is available
to all Hong Kong residents. The dataset covers a
population of approximately seven million. Data
were also sourced from the Japan Medical Data Cen-
ter insurance claims database (Japan, 2005–2010),
which represents a privately insured population of
approximately 300000 adult working population
and their dependents; however, there were insufﬁ-
cient records, and so data from this dataset were
not included in the study. Data from a hospital-based
database were also included, the Hamamatsu
Medical University Database, Japan (1999–2010).
The Japanese hospital dataset includes all patients
attending the hospital (approximately 175000) but
does not include community records.
A distributive network model was employed.3 Par-
ticipants created a dataset that included (i) a unique
patient identiﬁer; (ii) a variable to identify the med-
icine dispensed based on the World Health Organi-
zation standard anatomical therapeutic chemical
(ATC) code; and (iii) a variable to identify the date
of medicine supply. The coordinating center for this
Table 1. Prescription sequence symmetry analysis results for the associa-
tion between amiodarone and thyroxine: positive control
Country N pairs
Amiodarone
ﬁrst
Thyroxine
ﬁrst
Adjusted
sequence ratio,
95% conﬁdence
intervals
Australia 1979 1663 316 5.30 (4.69–5.96)
Hong Kong 754 529 225 2.33 (1.99–2.72)
Japan 16 11 5 1.77 (0.61–5.08)
Korea 657 453 204 1.52 (1.29–1.80)
Taiwan 153 115 38 3.26 (2.26–4.70)
Figure 1. Temporal analysis positive control: amiodarone-thyroxine, Australia
Figure 2. Pooled analysis positive control: amiodarone-thyroxine. CI, conﬁdence interval; SE, standard error
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study, the University of South Australia, developed
the statistical analysis code as a stand-alone Statisti-
cal Analysis System program for execution by each
participant. The SAS program employed global
macro variables that required participants to enter
the variable names used in their datasets rather than
forcing the creation of a data ﬁle with common data
variable names. This approach eliminates a complex
programming burden for participants and overcomes
barriers because of language and disparate data
structures. Participants executed the SAS code, and
a standardized summary results ﬁle was returned to
the coordinating center for collation. These standard-
ized ﬁles included graphs of the number of people
dispensed amiodarone, thyroxine, and allopurinol
each month (prevalent population), the number of
people starting amiodarone, thyroxine, and allopuri-
nol each month (incident population), and the pre-
scription symmetry analyses including the PSSA
distribution graphs, which display the temporal rela-
tionship between dispensing. Medicines were se-
lected by ATC codes in the Australian, Korean,
and Taiwanese datasets: amiodarone C01BD01, allo-
purinol M04AA01, and thyroxine H03AA01. Codes
for medicines in the Hong Kong and Japanese
datasets were mapped to the ATC codes.
Table 2. Prescription sequence symmetry analysis results for the associa-
tion between amiodarone and allopurinol: negative control
Country N pairs
Amiodarone
ﬁrst
Allopurinol
ﬁrst
Adjusted
sequence ratio,
95% conﬁdence
intervals
Australia 1002 493 509 0.99 (0.88–1.12)
Hong Kong 434 179 255 0.70 (0.58–0.85)
Japan 23 9 14 0.65 (0.28–1.49)
Korea 812 266 546 0.67 (0.57–0.77)
Taiwan 384 148 236 0.72 (0.59–0.88)
Figure 3. Temporal analysis negative control: amiodarone-allopurinol, Australia
Figure 4. Pooled analysis negative control: amiodarone-allopurinol. CI, conﬁdence interval; SE, standard error
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In the PSSA method, the date of incident dispensing
of amiodarone, thyroxine, and allopurinol was deter-
mined for each individual patient. All incident dis-
pensing that occurred within 1year of each other for
the same person were included in the analysis. We ex-
cluded patients who initiated any of the study medi-
cines in the ﬁrst year of data coverage in any dataset
to ensure we limited the analysis to incident users.
The crude sequence ratio (SR) was calculated by
dividing the number of persons with thyroxine initi-
ated after amiodarone initiation with the number of
persons with thyroxine initiated prior to amiodarone
initiation. The SR estimates the incidence rate ratio
of the event in exposed compared with non-exposed
person-time.14 The PSSA method uses a within-person
design, making it robust towards confounders that are
stable over time;1 however, it is sensitive to prescrib-
ing trends over time. Therefore, a null-effect SR was
calculated to adjust for temporal trends. The null-effect
SR is the expected SR in the absence of a causal asso-
ciation, given the incident medicine use and events in
the background population. A description of the for-
mula used for this value is provided elsewhere.14 An
adjusted SR was obtained by dividing the crude SR
by the null-effect SR, and 95%CI was calculated.
The same analyses were undertaken for amiodarone
and allopurinol, as well as thyroxine and allopurinol.
The PSSA analyses were restricted to sequences of
Table 3. Prescription sequence symmetry analysis results for the associa-
tion between thyroxine and allopurinol: negative control
Country N pairs
Thyroxine
ﬁrst
Allopurinol
ﬁrst
Adjusted
sequence ratio,
95% conﬁdence
intervals
Australia 1092 519 573 0.92 (0.82–1.04)
Hong Kong 215 105 110 0.97 (0.74–1.26)
Japan 47 31 16 1.73 (0.95–3.16)
Korea 933 471 462 1.05 (0.92–1.19)
Taiwan 105 43 62 0.74 (0.50–1.09)
Figure 5. Temporal analysis negative control: thyroxine-allopurinol, Australia
Figure 6. Pooled analysis negative control: thyroxine-allopurinol. CI, conﬁdence interval; SE, standard error
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incident dispensing within 12months of each other to
limit the effect of age and other potential time-varying
covariates on the probability of exposure and outcome.
Moreover, a 12-month period has better speciﬁcity and
positive predictive value compared with shorter pe-
riods.2 Pooled estimates were obtained by using the
generic inverse variance method.15
RESULTS
Positive control
Prescription sequence symmetry analysis identiﬁed
statistically signiﬁcant associations between incident
amiodarone use and subsequent initiation of thyroxine
in four of the ﬁve countries, with adjusted sequence ra-
tios ranging from 1.52 to 5.30 (Table 1). There were
only limited numbers of persons dispensed amioda-
rone in the Japanese dataset, so while the ratio was
positive, it did not reach a statistical signiﬁcance. Tem-
poral analysis showed that the observed effect of in-
creased thyroxine dispensing was evident within a
few weeks of initiation of therapy (Figure 1). This
temporal association was evident in all countries (data
not shown). The pooled estimate was 2.63 (95%CI
1.47–4.72, Figure 2).
Negative controls
The negative control of amiodarone and allopurinol
showed no positive association in any of the countries,
with adjusted sequence ratios ranging from 0.65 to
0.99 (Table 2). No temporal association was observed
(Figure 3). The pooled estimate was 0.76 (95%CI
0.62–0.93, Figure 4).
For the negative control of thyroxine and allopuri-
nol, no statistically signiﬁcant positive association
was observed; adjusted sequence ratios ranged from
0.74 to 1.73 (Table 3). No temporal association was
observed (Figure 5). The pooled estimate was 0.98
(95%CI 0.85–1.12, Figure 6).
DISCUSSION
In this study, we used one positive and two negative
controls to determine the risk, temporality, and consis-
tency of prescription symmetry results, using datasets
in different countries that included different age
groups, different ethnic groups, different health sys-
tems, different insurance systems, and different pat-
terns of utilization. In countries where there was
sufﬁcient sample size, the positive control analyses
showed a statistically signiﬁcant association. The
negative controls were not statistically signiﬁcantly
positive in any dataset.
Consistent with the ﬁndings within each country,
the pooled analyses showed a 2.6-fold increase in the
association of initiation of thyroxine after initiation
of amiodarone, while no effect was found in the
pooled analyses for either negative control. The tem-
poral results for amiodarone-induced thyroxine show
use of thyroxine increasing within the ﬁrst few weeks
of amiodarone initiation. Given the long half-life of
thyroxine, 6–7days, and the fact that the adverse event
is well known, it is likely that some degree of surveil-
lance bias may be present, resulting in early initiation
of thyroxine. These results reinforce the need to use
multiple datasets to support signal generation for ad-
verse event detection.
In one country, Japan, where a hospital only dataset
was used, one of the negative controls, thyroxine-
allopurinol, while not statistically signiﬁcant did have
an adjusted SR of 1.73. Hospital datasets, which may
have some outpatient data but do not usually capture
complete community medicine use, may contribute a
biased estimate if, in this example, either thyroxine
or allopurinol had signiﬁcant community dispensing
independent of hospital use. The extent of community
use in this example is unknown. Hospital only datasets
may be less suitable for routine surveillance using the
PSSA method unless both medicines are initiated in
the hospital setting.
In some countries, the negative control of
amiodarone-induced allopurinol prescribing gave a re-
sult suggestive of reduced risk of initiating allopurinol
after amiodarone. This pattern may represent detection
bias as allopurinol is not known to cause arrhythmia.13
It may be that patients presenting with gout, an acute
and painful condition that often precipitates a physi-
cian visit, are also assessed for other conditions at
the time of their presentation, and arrhythmia subse-
quently are detected at some stage in the following
1year time period.
In this study, we found that for a known positive and
two negative controls, the method produced consis-
tent, temporally associated results across countries, de-
spite different settings, health systems, ethnic groups,
and age groups. This provides further validation of
the method as a tool for signal detection across the As-
PEN. One of the advantages of PSSA is that the
graphic enables temporal relationships to be observed,
which demonstrates the strong temporal sequence for
the positive control in all countries. The major limita-
tion of the method is that it does not use diagnostic
criteria, thus speciﬁc adverse events are not detected,
rather medicines used to treat the adverse event are
n. pratt et al.
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used. This method, therefore, is reliant on the exis-
tence of a medicine that could be used to treat the
symptoms of the adverse event of interest. In
countries where full electronic health records are
available, the method could be trialed using speciﬁc
adverse events instead of a medicine indicator, for
example, hospitalization events with diagnostic
codes. The advantage of the method in using medi-
cine information is that it can be used to support
pharmacovigilance in many countries that routinely
collect dispensing data in electronic format in an
efﬁcient manner, alongside signal detection methods
from spontaneous reporting systems.
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